$JNJ Recent Headlines Republican victory will
Post# of 102791
Posted On: 11/10/2014 10:18:15 AM
$JNJ Recent Headlines
Republican victory will boost these 21 stocks 7:45 a.m. Nov. 5, 2014 - Michael Brush
Ebola play Halyard Health stock gains are modest 1:02 p.m. Nov. 3, 2014 - Russ Britt
Ebola-nation travelers to U.S. to be watched 21 days 3:04 p.m. Oct. 22, 2014 - Russ Britt
Johnson & Johnson to begin testing Ebola vaccine in January 9:14 a.m. Oct. 22, 2014 - Jonathan D. Rockoff
A possible new Ebola vaccine from Johnson&Johnson 4:32 a.m. Oct. 22, 2014 - MarketWatch
Fighting Ebola though investing: one firm’s approach 6:42 p.m. Oct. 21, 2014 - Wallace Witkowski
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
Updates, advisories and surprises 5:31 p.m. Oct. 14, 2014 - MarketWatch
Delta, Citigroup gain; J.P. Morgan, Wells Fargo slide following results 10:58 a.m. Oct. 14, 2014 - Sue Chang
Newscast: Google launches same-day delivery 9:58 a.m. Oct. 14, 2014 - MarketWatch
All the reasons to sell this market are enough to draw a guy in 9:23 a.m. Oct. 14, 2014 - Shawn Langlois
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Johnson & Johnson shares gain after profit beat, raised outlook 7:59 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson shares up 1% premarket after Q3 results 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson ups 2014 EPS outlook to $5.92-$5.97 from $5.85-$5.92 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 net EPS $1.66 vs. $1.04 a year ago 7:49 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales of $18.5 bln vs. FactSet consensus $18.44 bln 7:48 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales up 5.1% from last year to $18.5 bln 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 adj. EPS $1.50 vs. FactSet consensus $1.45 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore
What to expect from Johnson & Johnson’s earnings 7:09 a.m. Oct. 14, 2014 - Tomi Kilgore
Dendreon to Pursue Sale or Reorganization in Bankruptcy 46 min ago - The Wall Street Journal Interactive Edition
Merck triple therapy HCV candidate fails as a four-week regimen 7:49 a.m. Today - Seeking Alpha
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy 7:12 a.m. Today - TheStreet.com
Wall Street Breakfast: Dendreon Files For Chapter 11 Bankruptcy 6:31 a.m. Today - Seeking Alpha
J&J Seeks Acquisitions in China 3:04 a.m. Today - The Wall Street Journal Interactive Edition
Bristol-Myers presents data on HCV Trio regimen 6:04 p.m. Nov. 9, 2014 - Seeking Alpha
Bristol-Myers presents data on shorter regimen HCV drug combo 5:37 p.m. Nov. 9, 2014 - Seeking Alpha
Achillion presents HCV data at The Liver Meeting 5:06 p.m. Nov. 9, 2014 - Seeking Alpha
Retirement Strategy: The Politics That Could Affect Our Retirement Portfolios And Income 11:04 a.m. Nov. 9, 2014 - Seeking Alpha
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog 6:50 p.m. Nov. 7, 2014 - Zacks.com
My Challenges As A Dividend Growth Investor 5:34 p.m. Nov. 7, 2014 - Seeking Alpha
Retirement Strategy: One Basic Flaw Of Dividend Growth Investing 4:22 p.m. Nov. 7, 2014 - Seeking Alpha
Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled? 2:52 p.m. Nov. 6, 2014 - Seeking Alpha
Style Rankings For ETFs And Mutual Funds 8:40 a.m. Nov. 6, 2014 - Seeking Alpha
Biosimilars: The Good, the Bad and the Unknown 7:27 a.m. Nov. 6, 2014 - Barrons.com
FDA clears HCV combo 7:08 a.m. Nov. 6, 2014 - Seeking Alpha
Best ETFs For Large-Cap Value 4:45 a.m. Nov. 6, 2014 - InvestorPlace.com
Buy These 5 Healthy Blue Chips with Growing Dividends 3:28 a.m. Nov. 6, 2014 - InvestorPlace.com
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog 12:00 p.m. Nov. 5, 2014 - Zacks.com
Tracking Yacktman Asset Management Portfolio - Q3 2014 Update 6:56 a.m. Nov. 5, 2014 - Seeking Alpha
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 54 min ago - ACCESSWIRE
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership 8:35 a.m. Today - PR Newswire - PRF
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 8:03 a.m. Today - BusinessWire - BZX
New President and New Offices Signal New Era for New Jersey-based BNO 6:36 p.m. Nov. 7, 2014 - PR Newswire - PRF
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition 4:05 p.m. Nov. 7, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting 4:20 p.m. Nov. 6, 2014 - Marketwired
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50 9:26 a.m. Nov. 5, 2014 - ACCESSWIRE
Baron and Budd Investigating Potential Xarelto Lawsuits 4:03 p.m. Nov. 4, 2014 - BusinessWire - BZX
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations 5:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019 8:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 1:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Johnson & Johnson Diabetes Solutions Companies Join The Joslin Institute for Technology Translation (JITT) As Founding Members 9:00 a.m. Oct. 30, 2014 - BusinessWire - BZX
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation 5:15 a.m. Oct. 29, 2014 - Thomson Reuters ONE
Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
GTCR Announces Sale of Devicor Medical Products 7:32 a.m. Oct. 28, 2014 - BusinessWire - BZX
Global and China Monoclonal Antibody Industry Report, 2014-2019 9:26 p.m. Oct. 27, 2014 - PR Newswire - PRF
Axxess Pharma Retains Natural Products Consulting Institute "NPCI" for Health Canada Approval of TapouT High Potency Omega-3 Fish Oil and TapouT Turbo Blend Protein Powder 8:02 a.m. Oct. 23, 2014 - Marketwired
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets 5:47 p.m. Oct. 22, 2014 - Thomson Reuters ONE
Republican victory will boost these 21 stocks 7:45 a.m. Nov. 5, 2014 - Michael Brush
Ebola play Halyard Health stock gains are modest 1:02 p.m. Nov. 3, 2014 - Russ Britt
Ebola-nation travelers to U.S. to be watched 21 days 3:04 p.m. Oct. 22, 2014 - Russ Britt
Johnson & Johnson to begin testing Ebola vaccine in January 9:14 a.m. Oct. 22, 2014 - Jonathan D. Rockoff
A possible new Ebola vaccine from Johnson&Johnson 4:32 a.m. Oct. 22, 2014 - MarketWatch
Fighting Ebola though investing: one firm’s approach 6:42 p.m. Oct. 21, 2014 - Wallace Witkowski
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
Updates, advisories and surprises 5:31 p.m. Oct. 14, 2014 - MarketWatch
Delta, Citigroup gain; J.P. Morgan, Wells Fargo slide following results 10:58 a.m. Oct. 14, 2014 - Sue Chang
Newscast: Google launches same-day delivery 9:58 a.m. Oct. 14, 2014 - MarketWatch
All the reasons to sell this market are enough to draw a guy in 9:23 a.m. Oct. 14, 2014 - Shawn Langlois
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Johnson & Johnson shares gain after profit beat, raised outlook 7:59 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson shares up 1% premarket after Q3 results 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson ups 2014 EPS outlook to $5.92-$5.97 from $5.85-$5.92 7:50 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 net EPS $1.66 vs. $1.04 a year ago 7:49 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales of $18.5 bln vs. FactSet consensus $18.44 bln 7:48 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 sales up 5.1% from last year to $18.5 bln 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore
Johnson & Johnson Q3 adj. EPS $1.50 vs. FactSet consensus $1.45 7:47 a.m. Oct. 14, 2014 - Tomi Kilgore
What to expect from Johnson & Johnson’s earnings 7:09 a.m. Oct. 14, 2014 - Tomi Kilgore
Dendreon to Pursue Sale or Reorganization in Bankruptcy 46 min ago - The Wall Street Journal Interactive Edition
Merck triple therapy HCV candidate fails as a four-week regimen 7:49 a.m. Today - Seeking Alpha
The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy 7:12 a.m. Today - TheStreet.com
Wall Street Breakfast: Dendreon Files For Chapter 11 Bankruptcy 6:31 a.m. Today - Seeking Alpha
J&J Seeks Acquisitions in China 3:04 a.m. Today - The Wall Street Journal Interactive Edition
Bristol-Myers presents data on HCV Trio regimen 6:04 p.m. Nov. 9, 2014 - Seeking Alpha
Bristol-Myers presents data on shorter regimen HCV drug combo 5:37 p.m. Nov. 9, 2014 - Seeking Alpha
Achillion presents HCV data at The Liver Meeting 5:06 p.m. Nov. 9, 2014 - Seeking Alpha
Retirement Strategy: The Politics That Could Affect Our Retirement Portfolios And Income 11:04 a.m. Nov. 9, 2014 - Seeking Alpha
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog 6:50 p.m. Nov. 7, 2014 - Zacks.com
My Challenges As A Dividend Growth Investor 5:34 p.m. Nov. 7, 2014 - Seeking Alpha
Retirement Strategy: One Basic Flaw Of Dividend Growth Investing 4:22 p.m. Nov. 7, 2014 - Seeking Alpha
Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled? 2:52 p.m. Nov. 6, 2014 - Seeking Alpha
Style Rankings For ETFs And Mutual Funds 8:40 a.m. Nov. 6, 2014 - Seeking Alpha
Biosimilars: The Good, the Bad and the Unknown 7:27 a.m. Nov. 6, 2014 - Barrons.com
FDA clears HCV combo 7:08 a.m. Nov. 6, 2014 - Seeking Alpha
Best ETFs For Large-Cap Value 4:45 a.m. Nov. 6, 2014 - InvestorPlace.com
Buy These 5 Healthy Blue Chips with Growing Dividends 3:28 a.m. Nov. 6, 2014 - InvestorPlace.com
Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog 12:00 p.m. Nov. 5, 2014 - Zacks.com
Tracking Yacktman Asset Management Portfolio - Q3 2014 Update 6:56 a.m. Nov. 5, 2014 - Seeking Alpha
VYCOR: "On the Cusp of the Next Big Healthcare Trend" 54 min ago - ACCESSWIRE
HackerAgency Names New Director of Strategic Planning; Adds Senior Client Leadership 8:35 a.m. Today - PR Newswire - PRF
Biosense Webster Teams Up with StopAfib.org to Challenge Americans to Get SMART About AfibSM 8:03 a.m. Today - BusinessWire - BZX
New President and New Offices Signal New Era for New Jersey-based BNO 6:36 p.m. Nov. 7, 2014 - PR Newswire - PRF
Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition 4:05 p.m. Nov. 7, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting 4:20 p.m. Nov. 6, 2014 - Marketwired
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50 9:26 a.m. Nov. 5, 2014 - ACCESSWIRE
Baron and Budd Investigating Potential Xarelto Lawsuits 4:03 p.m. Nov. 4, 2014 - BusinessWire - BZX
Legal-Bay Lawsuit Settlement Funding Updates News on All Major Hip Litigations 5:00 a.m. Nov. 4, 2014 - PR Newswire - PRF
Coronary Stents Market (Bare Metal Stents, Drug Eluting Stents and Bio-absorbable Stents) - Global Industry Analysis, Size, Share, Pipeline Overview, Growth, Trends and Forecast, 2013 - 2019 8:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 1:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire 9:15 a.m. Oct. 30, 2014 - PR Newswire - PRF
Johnson & Johnson Diabetes Solutions Companies Join The Joslin Institute for Technology Translation (JITT) As Founding Members 9:00 a.m. Oct. 30, 2014 - BusinessWire - BZX
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation 5:15 a.m. Oct. 29, 2014 - Thomson Reuters ONE
Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances 4:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
GTCR Announces Sale of Devicor Medical Products 7:32 a.m. Oct. 28, 2014 - BusinessWire - BZX
Global and China Monoclonal Antibody Industry Report, 2014-2019 9:26 p.m. Oct. 27, 2014 - PR Newswire - PRF
Axxess Pharma Retains Natural Products Consulting Institute "NPCI" for Health Canada Approval of TapouT High Potency Omega-3 Fish Oil and TapouT Turbo Blend Protein Powder 8:02 a.m. Oct. 23, 2014 - Marketwired
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets 5:47 p.m. Oct. 22, 2014 - Thomson Reuters ONE
(0)
(0)